Does the magnitude of OncoType recurrence score above 26 inform decision between TC and AC/T in ER+ HER2- 1-3 node positive, postmenopausal patients with breast cancer?

We don't have any evidence for correlating recurrence score with choice of chemotherapy. Based on RxPONDER, we know that patients with 1-3 positive lymph nodes and scores less than 25, do not benefit from chemotherapy. Based on retrospective data, we have enough evidence that scores more than 30 wou...